CBX

 China CDE has approved Glubio's GLB-001, a CK1α degrader, for the Investigational New Drug (IND) application in patients with myeloid neoplasm (AML/MDS). Glubio Therapeutics submitted the IND application on December 9th, 2023.  The FDA cleared the IND application for GLB-001 in April 2023, and the first-in-human trial ( NCT06146257 ) was initiated in January 2024, focusing on patients with relapsed or refractory acute myeloid leukemia (R/R AML) or higher-risk myelodysplastic syndromes (R/R HR-MDS). GLB-001 is a molecular glue targeting CK1α, different from their second degrader GLB-002, which is targeting Aiolos and Ikaros. Casein kinase 1 alpha ( CK1α ), encoded by gene CSNK1A1, is a ubiquitously expressed serine/threonine protein kinase in the CK1 kinase family. CK1α, as a key regulator of the Wnt/β-catenin pathway, directly phosphorylates β-catenin at Ser45 and thereby targets it for proteasomal degradation. CK1α was also known to regulate the protein stability of tumor suppr